viewAchieve Life Sciences Inc

Achieve Life Sciences shares rise on release of new plan for smoking cessation drug

A recent meeting with the US Food and Drug Administration has outlined the next stages required to bring cytisine to market

Cigarette butts
Cytisine has been used as a smoking cessation treatment in Central and Eastern Europe for more than 15 years

\Achieve Life Sciences Inc (NASDAQ:ACHV) shares are soaring in pre-market trading in the wake of the release of its updated development plan for cytisine, its smoking cessation drug.

Prior to the opening bell, Achieve shares jumped 43% to US$5.17.

A recent meeting with the US Food and Drug Administration makes clear the next stages required before Achieve can bring cytisine to market.

“The successful outcome of our discussions with the FDA has provided us with clarity and direction to better inform our Phase 3 clinical development program and our efforts toward expanding cytisine availability,” said Rich Stewart, chief executive of Achieve Life Sciences.

Read: Achieve Life Sciences shares slump on its public stock offering

Taking into account the FDA’s recommendations, Achieve is now set to conduct a Phase 2b optimization trial, which will evaluate 250 smokers in the US and use various cytisine dosing schedules over a 25-day period.

The primary goal of the trial will be to see if the number of cigarettes smoked during treatment is reduced.

Cytisine is a plant-based alkaloid with a high-binding affinity to the nicotinic acetylcholine receptor. It has been used as a smoking cessation treatment across Central and Eastern Europe for more than 15 years.

Achieve will kick off its Phase 2b trial in the fourth quarter of this year and expects to report top-line results for the study by the second quarter of next year.

Once the results from this Phase 2b trial are released, Achieve plans to begin its Phase 3 program for cytisine next year.

Quick facts: Achieve Life Sciences Inc

Price: 0.3984 USD

Market: NASDAQ
Market Cap: $14.95 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...



Salt Lake Potash welcomes key new strategic investor as part of A$15mln funding

Salt Lake Potash Ltd's (ASX:SO4) Tony Swiericzuk speaks to Proactive after announcing a A$10 million strategic investment from Equatorial Resources Ltd (ASX:EQX) as part of a A$15 million placement of convertible notes to corporate and institutional investors. Salt Lake is in the final stages of...

21 hours ago

2 min read